Figure 5.

The Role of ICI Scores in the Prediction of Immunotherapeutic Benefits

(A) ICI scores in groups with a different anti-PD-1 clinical response status. Wilcoxon test, p < 0.0001. (B) Kaplan-Meier curves for patients with high and low ICI scores in the IMvigor210 cohort. Log rank test, p = 0.0017. (C) Rate of clinical response (complete response [CR]/partial response [PR] and stable disease [SD]/progressive disease [PD]) to anti-PD-L1 immunotherapy in high or low ICI score groups in the IMvigor210 cohort. (D) Distribution of ICI score in different response status to immunotherapy in the TCGA-SKCM cohort. Wilcoxon test, p = 0.041. (E) Kaplan-Meier curves for patients with high and low ICI scores in the TCGA-SKCM cohort. Log rank test, p = 0.047. (F) Rate of clinical response (CR/PR and SD/PD) to various immunotherapies in high or low ICI score groups in the TCGA-SKCM cohort.